Pharmacogenomic Data Might Suffice For Retrospective Analysis, FDA's Temple Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trials could be examined in a two-step process, Office of Medical Policy Director Temple says during workshop on pharmacogenomics in drug development. The data from the second half a trial could test a hypothesis generated from examining the first half if the data are "very persuasive."You may also be interested in...
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
FDA Risk Communication Research May Follow Critical Path To Avoid OMB
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: